FDA Approves Risankizumab (Skyrizi) for Psoriatic Arthritis FDA Approves Risankizumab (Skyrizi) for Psoriatic Arthritis
The approval is the second indication for the anti-interleukin 23 monoclonal antibody after approval for plaque psoriasis was granted in 2019.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 22, 2022 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

Secukinumab vs. Adalimumab in Psoriatic Arthritis and Psoriasis Secukinumab vs. Adalimumab in Psoriatic Arthritis and Psoriasis
The results of this study provide evidence that the IL-17 inhibitor secukinumab is effective in managing the concomitant features of psoriasis and psoriatic arthritis.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 4, 2022 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Novartis Cosentyx Receives FDA Approval for the Treatment of Children and Adolescents with Enthesitis-Related Arthritis and Psoriatic Arthritis
- New approvals are based on JUNIPERA trial data showing Cosentyx® (secukinumab) demonstrated reduced flare risk versus placebo and improvement in disease activity observed over two years across both enthesitis-related arthritis (ERA)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 22, 2021 Category: Drugs & Pharmacology Source Type: news

Serum Biomarkers Can Differentiate Psoriatic Arthritis, RA
TUESDAY, Dec. 21, 2021 -- A serum protein biomarker panel can differentiate patients with early inflammatory arthritis with psoriatic arthritis (PsA) from those with rheumatoid arthritis (RA), according to a study recently published in Arthritis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Upadacitinib (Rinvoq) for Psoriatic Arthritis FDA Approves Upadacitinib (Rinvoq) for Psoriatic Arthritis
The approval of upadacitinib 15 mg for adults with psoriatic arthritis is the second indication for the JAK inhibitor after it was first approved for rheumatoid arthritis in 2019.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - December 15, 2021 Category: Dermatology Tags: Rheumatology News Alert Source Type: news

Episode 2: How to Integrate Wellness into Psoriatic Arthritis Care Episode 2: How to Integrate Wellness into Psoriatic Arthritis Care
What steps do these busy clinicians take to keep their patients trending toward the healthy side of the health-illness continuum?Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 15, 2021 Category: Consumer Health News Tags: None InDiscussion Source Type: news

Episode 1: Defining and Measuring Wellness in Psoriatic Arthritis Episode 1: Defining and Measuring Wellness in Psoriatic Arthritis
Clinical experts in rheumatology and integrative medicine discuss the realm of wellness in psoriatic arthritis care.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 15, 2021 Category: Consumer Health News Tags: None InDiscussion Source Type: news

Rinvoq (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis
NORTH CHICAGO, Ill., Dec. 14, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 14, 2021 Category: Drugs & Pharmacology Source Type: news

Patient Pathways to Diagnosis of Psoriatic Arthritis Patient Pathways to Diagnosis of Psoriatic Arthritis
Gain a better understanding of the symptoms that may precede a psoriatic arthritis diagnosis and patients'experiences in obtaining the diagnosis.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 14, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Malignancy Risk in Patients With Secukinumab-treated Psoriasis Malignancy Risk in Patients With Secukinumab-treated Psoriasis
Does treatment with secukinumab increase the risk of malignancy in patients being treated for psoriasis, psoriatic arthritis, or ankylosing spondylitis?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 14, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Latest Phase 3 Data for First-in-Class TREMFYA ® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, December 3, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheumatic Diseases (ARD), evaluating this selective interleukin (IL)-23 inhibitor in adults with active psoriatic arthritis (PsA) who demonstrated inadequate efficacy or intolerance to tumor necrosis factor inhibition (TNFi).1 Results showed significantly higher proportions of patients treated with TREMFYA had improvement in joint signs and symptoms and complete skin clearance versus...
Source: Johnson and Johnson - December 3, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Guselkumab Deemed Effective for PsA Previously Treated With TNFi Guselkumab Deemed Effective for PsA Previously Treated With TNFi
COSMOS trial results in patients with psoriatic arthritis fit with the expectation that"people who've previously failed a TNF inhibitor might be a little less likely to respond to guselkumab."Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - December 2, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

Psoriatic Arthritis Highlights From ACR 2021 Psoriatic Arthritis Highlights From ACR 2021
Dr Christopher Ritchlin discusses key reports on psoriatic arthritis from ACR 2021, including results of a brepocitinib efficacy study and data on risk factors for progression and patient concerns.Medscape (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 24, 2021 Category: Orthopaedics Tags: Rheumatology ReCAP Source Type: news

Psoriatic Arthritis: Looking for the Unexpected Psoriatic Arthritis: Looking for the Unexpected
Jennifer Kwan-Morley, MD, discusses advances in the treatment of psoriatic arthritis that she has witnessed in her career.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 23, 2021 Category: Consumer Health News Tags: None MDAngle Source Type: news

Psoriatic Arthritis: The Importance of Multidisciplinary Teams and Mentors Psoriatic Arthritis: The Importance of Multidisciplinary Teams and Mentors
Jennifer Kwan-Morley, MD, reflects on the mentors who helped shape her approach to psoriatic arthritis.Medscape (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 22, 2021 Category: Orthopaedics Tags: Rheumatology MDAngle Source Type: news

Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news

Psoriatic Arthritis Management: From Intramuscular Gold to Biologics Psoriatic Arthritis Management: From Intramuscular Gold to Biologics
Phillip J. Mease, MD, reflects on the development of therapeutics for psoriatic arthritis, from intramuscular gold and oral methotrexate in former decades, to the recent use of biologics.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 11, 2021 Category: Consumer Health News Tags: Rheumatology MDAngle Source Type: news

How the COVID-19 Pandemic Has Affected Psoriatic Arthritis Care How the COVID-19 Pandemic Has Affected Psoriatic Arthritis Care
Saakshi Khattri, MD, discussing navigating the first days of the COVID-19 pandemic with her psoriatic arthritis patients.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2021 Category: Consumer Health News Tags: None MDAngle Source Type: news

Risankizumab Outperforms Placebo at 6 Months for Psoriatic Arthritis Risankizumab Outperforms Placebo at 6 Months for Psoriatic Arthritis
At the 24-week assessment, participants receiving risankizumab showed greater improvement in primary and secondary endpoints than did placebo with no new safety signals.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 8, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

Three Signs Point to a Diagnosis of Psoriatic Arthritis Three Signs Point to a Diagnosis of Psoriatic Arthritis
Dactylitis, an inflamed sausage-like finger or toe, is a classic finding of psoriatic arthritis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 7, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

A Look Ahead: The Goal of Precision Medicine in Psoriatic Arthritis A Look Ahead: The Goal of Precision Medicine in Psoriatic Arthritis
How Saakshi Khattri, MD, envisions a future of precision medicine in psoriatic arthritis.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 4, 2021 Category: Consumer Health News Tags: None MDAngle Source Type: news

New Comprehensive Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years
SPRING HOUSE, PENNSYLVANIA, November 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced comprehensive efficacy and safety data from the DISCOVER–2 trial of TREMFYA® (guselkumab) were published in Arthritis & Rheumatology, representing the final results of the first two-year clinical trial investigating a selective interleukin (IL)-23 inhibitor therapy in active psoriatic arthritis (PsA).1 Results show a majority of TREMFYA-treated biologic-naïve adult patients with active PsA achieved improvements in joint signs and symptoms (American College of Rheumatology [AC...
Source: Johnson and Johnson - November 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Higher Odds for Preterm, C-Section Births Seen in Women With PsA Higher Odds for Preterm, C-Section Births Seen in Women With PsA
Pregnant women with psoriatic arthritis may have an increased risk for preterm birth or cesarean delivery if they are receiving antirheumatic drugs such as biologics.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 25, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately t...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Reports Q3 2021 Results
New Brunswick, N.J. (October 19, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2021. “Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health,” said Alex Gorsky, Chairman and Chief Executive Officer. “In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of ou...
Source: Johnson and Johnson - October 19, 2021 Category: Pharmaceuticals Tags: Financial Source Type: news

Arthritis: Best anti-inflammatory beverage to provide effective pain relief for joints
INFLAMMATORY arthritis is characterised by painful, swollen and tender joints. Common forms include: rheumatoid arthritis , psoriatic arthritis , systemic lupus erythematosus , gout and ankylosing spondylitis . (Source: Daily Express - Health)
Source: Daily Express - Health - October 8, 2021 Category: Consumer Health News Source Type: news

Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associa...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque p...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

More Severe Psoriasis Linked to an Increased Risk of PsA More Severe Psoriasis Linked to an Increased Risk of PsA
"Timely and accurate diagnosis of psoriatic arthritis (PsA) is important for improved patient outcomes and appropriate disease management."Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 1, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

Psoriatic Arthritis Detection: Screening Tools for Dermatologists Psoriatic Arthritis Detection: Screening Tools for Dermatologists
Drs Joseph Merola and Alice Gottlieb discuss the importance of diagnosing psoriatic arthritis and tips for screening among patients with psoriasis.Medscape Dermatology (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 27, 2021 Category: Dermatology Tags: Dermatology Commentary Source Type: news

Medicare Patients' Psoriasis, PsA Drug Costs Remain High Medicare Patients' Psoriasis, PsA Drug Costs Remain High
Coverage of and access to biologics for psoriasis and psoriatic arthritis are compromised by out-of-pocket payments and prior authorization requirements.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 16, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

Cannabidiol Found No Better Than Placebo for Hand Arthritis Pain Cannabidiol Found No Better Than Placebo for Hand Arthritis Pain
Patients with hand osteoarthritis or psoriatic arthritis who used cannabidiol as an add-on analgesic had results similar to those of placebo.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 16, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

Consider Itch and Joint Pain in Pediatric Psoriasis Patients Consider Itch and Joint Pain in Pediatric Psoriasis Patients
About 1% of pediatric psoriasis patients have psoriatic arthritis, which is much less common than in adults is"but important to find and manage."Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 3, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

Treatment With Guselkumab Resolves Enthesitis in Psoriatic Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - August 28, 2021 Category: Orthopaedics Tags: Perspective Source Type: news

Psoriatic Arthritis Worsens QoL in Patients With Psoriasis
Individuals with psoriasis/PsA have decreased ability to participate in social roles and activities, more depression symptoms (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - August 25, 2021 Category: Psychiatry Tags: Dermatology, Family Medicine, Internal Medicine, Psychiatry, Rheumatology, Journal, Source Type: news

Psoriatic Arthritis Worsens QoL in Patients With Psoriasis
WEDNESDAY, Aug. 25, 2021 -- People with psoriasis/psoriatic arthritis (PsA) have a decreased ability to participate in social roles and activities and more depressive symptoms than those with psoriasis alone, according to a research letter published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 25, 2021 Category: Pharmaceuticals Source Type: news

Physicians Question Future of TNF Inhibitors for Psoriasis, PsA Physicians Question Future of TNF Inhibitors for Psoriasis, PsA
Two dermatologists and two rheumatologists debate the merits of using IL-17 and IL-23 inhibitors ahead of TNF inhibitors for the treatment of psoriasis and psoriatic arthritis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 9, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

Papers on COVID-19 in Psoriasis, Psoriatic Arthritis Carry Risk for Bias
WEDNESDAY, Aug. 4, 2021 -- Published papers addressing the risk and outcomes of COVID-19 in patients with psoriasis and psoriatic arthritis receiving biologic therapies have a high risk for bias, according to a study published online Aug. 4 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 4, 2021 Category: Pharmaceuticals Source Type: news

How Do You Get a Psoriatic Arthritis Diagnosis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 26, 2021 Category: General Medicine Source Type: news

What Is the Life Expectancy of Someone With Psoriatic Arthritis?
Title: What Is the Life Expectancy of Someone With Psoriatic Arthritis?Category: Diseases and ConditionsCreated: 7/23/2021 12:00:00 AMLast Editorial Review: 7/23/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 23, 2021 Category: Rheumatology Source Type: news

Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Does Psoriatic Arthritis Affect Elbows
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 21, 2021 Category: General Medicine Source Type: news

What Is the Safest Drug for Psoriatic Arthritis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 21, 2021 Category: General Medicine Source Type: news

How Do You Describe Psoriatic Arthritis Pain
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 21, 2021 Category: General Medicine Source Type: news

CBD for Psoriasis and Psoriatic Arthritis: What You Should Know
CBD is growing in popularity, and there are many over-the-counter skin products infused with CBD. While CBD can provide some pain relief to psoriasis and psoriatic arthritis, experts say there needs to be more research. (Source: WebMD Health)
Source: WebMD Health - July 20, 2021 Category: Consumer Health News Source Type: news

What Is the Life Expectancy of Psoriatic Arthritis
What Is the Life Expectancy of Someone with Psoriatic Arthritis? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 19, 2021 Category: General Medicine Source Type: news

What Are the Five Types of Psoriatic Arthritis?
Title: What Are the Five Types of Psoriatic Arthritis?Category: Diseases and ConditionsCreated: 7/13/2021 12:00:00 AMLast Editorial Review: 7/13/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 13, 2021 Category: Rheumatology Source Type: news

How Is Psoriatic Arthritis Diagnosed?
Title: How Is Psoriatic Arthritis Diagnosed?Category: Diseases and ConditionsCreated: 7/12/2021 12:00:00 AMLast Editorial Review: 7/12/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 12, 2021 Category: Rheumatology Source Type: news

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being pr...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Tips for Managing Psoriatic Arthritis
Medical treatment for your psoriatic arthritis (PsA) is essential for managing symptoms and protecting your joints. Add these daily practices to help with joint health and keep flare-ups at bay. (Source: WebMD Health)
Source: WebMD Health - July 8, 2021 Category: Consumer Health News Source Type: news